Literature DB >> 9694929

Holtzman and Harlan Sprague-Dawley rats: differences in DRL 72-sec performance and 8-hydroxy-di-propylamino tetralin-induced hypothermia.

M Balcells-Olivero1, M S Cousins, L S Seiden.   

Abstract

Several compounds were tested on the differential-reinforcement-of-low-rate 72-sec (DRL 72-sec) schedule, a behavioral screen to determine putative antidepressants; these compounds were evaluated in two outbred stocks of rats, Harlan and Holtzman Sprague-Dawley rats. A dose-response determination for the tricyclic antidepressants, imipramine and desipramine, the selective serotonin (5-hydroxytryptamine; 5-HT) reuptake inhibitor, fluoxetine, the 5-HT2 receptor antagonist, ketanserin, the 5-HT1A receptor agonist, (+/-)8-hydroxy-di-propylamino tetralin (8-OH-DPAT) and the dopamine releasing compound, amphetamine, were assessed in both rat stocks. The two stocks of rats differed in their baseline performance on the DRL 72-sec schedule. The Harlan rats had a higher reinforcement rate and a lower response rate than the Holtzman rats. In Holtzman, but not in Harlan rats, imipramine, ketanserin, fluoxetine and 8-OH-DPAT increased reinforcement rate and decreased response rate on the DRL 72-sec schedule, confirming previous studies. However, desipramine was the only drug to increase reinforcement rate and decrease response rate in both Holtzman and Harlan rats; in Harlan rats, drugs that primarily act upon the 5-HT system, imipramine, ketanserin, fluoxetine and 8-OH-DPAT, disrupted the DRL 72-sec performance and did not increase the number of reinforcements over baseline as was seen in Holtzman rats. Amphetamine disrupted DRL 72-sec performance in both Holtzman and Harlan rats in a similar manner. The hypothermic response to 8-OH-DPAT was also assessed in the two stocks of rats; Holtzman rats had a smaller decrease in core body temperature than Harlan rats. The observed behavioral and pharmacological differences between Holtzman and Harlan rat stocks may be genetically and/or environmentally mediated.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9694929

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  9 in total

Review 1.  The recombinant 5-HT1A receptor: G protein coupling and signalling pathways.

Authors:  J R Raymond; Y V Mukhin; T W Gettys; M N Garnovskaya
Journal:  Br J Pharmacol       Date:  1999-08       Impact factor: 8.739

2.  5-HT(1A) Receptor Null Mutant Mice Responding Under a Differential-Reinforcement-of-Low-Rate 72-Second Schedule of Reinforcement.

Authors:  Jonah J Scott-McKean; Galen R Wenger; Laurence H Tecott; Alberto C S Costa
Journal:  Open Neuropsychopharmacol J       Date:  2008-01-01

3.  Maternal iron supplementation attenuates the impact of perinatal copper deficiency but does not eliminate hypotriiodothyroninemia nor impaired sensorimotor development.

Authors:  Thomas W Bastian; Katie C Lassi; Grant W Anderson; Joseph R Prohaska
Journal:  J Nutr Biochem       Date:  2011-01-15       Impact factor: 6.048

Review 4.  The genetic basis of delay discounting and its genetic relationship to alcohol dependence.

Authors:  Suzanne H Mitchell
Journal:  Behav Processes       Date:  2011-02-24       Impact factor: 1.777

5.  Timing and space usage are disrupted by amphetamine in rats maintained on DRL 24-s and DRL 72-s schedules of reinforcement.

Authors:  Stephen C Fowler; Jonathan Pinkston; Elena Vorontsova
Journal:  Psychopharmacology (Berl)       Date:  2009-01-14       Impact factor: 4.530

6.  The effects of clinically relevant doses of amphetamine and methylphenidate on signal detection and DRL in rats.

Authors:  Matthew E Andrzejewski; Robert C Spencer; Rachel L Harris; Elizabeth C Feit; Brenda L McKee; Craig W Berridge
Journal:  Neuropharmacology       Date:  2014-01-24       Impact factor: 5.250

7.  Mother-infant separation leads to hypoactive behavior in adolescent Holtzman rats.

Authors:  Jaclyn Spivey; Douglas Barrett; Eimeira Padilla; F Gonzalez-Lima
Journal:  Behav Processes       Date:  2008-05-24       Impact factor: 1.777

8.  Optimal temporal risk assessment.

Authors:  Fuat Balci; David Freestone; Patrick Simen; Laura Desouza; Jonathan D Cohen; Philip Holmes
Journal:  Front Integr Neurosci       Date:  2011-09-27

Review 9.  Targeting G protein coupled receptor-related pathways as emerging molecular therapies.

Authors:  Abdelaziz Ghanemi
Journal:  Saudi Pharm J       Date:  2013-08-13       Impact factor: 4.330

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.